Desloratadine in Patients With Ulcerative Colitis

NCT07333716 · tracked via the Priya Life Science Egypt tracker

Sponsor

Tanta University

Phase

Phase 2

Started

2026-01-26

Last updated

2026-01-29

Condition(s) studied

Ulcerative Colitis (UC)Ulcerative Colitis

Investigational drug(s) / intervention(s)

Desloratadine →mesalamine →

Desloratadine: mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.

mesalamine: mesalamine 1000 mg three times daily for 3 months

Study summary

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Both male and female sex. * patients with age ranged from 18 to 65. * patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline. * Patients treated with 5-aminosalisylic acid (mesalamine). Exclusion Criteria: * Patients with severe UC * Significant liver or kidney function abnormalities * Pregnant or lactating females * Treatment with systemic or rectal steroids * Treatment with immunosuppressant or biological therapies * Known allergy to desloratadine or any ingredient in the formulation * Patients with other inflammatory diseases * Patients with history of colon cancer * Patients with complete or partial colectomy

Primary outcome measure(s)

Change in disease activity and severity — over a 3 month follow -up period
Change in disease activity and severity through Partial Mayo Scoring Index (PMSI) and Truelove and Witt's classification

Trial sites (1)

Facility	City	Region	Status
Menofia university Hospitals	Shibīn al Kawm	Menofia	Recruiting

More Tanta University trials in Egypt

Metformin as Added on Therapy in Patients With Ulcerative Colitis Recruiting

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection Recruiting

The Effect of Preoperative Administration of Oral Tizanidine on the Postoperative Pain and Sleep Quality Recruiting

Patient and Operator Centered Outcomes Concerning Connective Tissue Graft Should Be Considered to Choose Adequately Which Protocol to Use Active, not recruiting

Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease Recruiting

Other trials for the same condition

Palmitoylethanolamide in Ulcerative Colitis Recruiting

Urinary PGE-MUM as a Marker for Ulcerative Colitis Activity Starting soon

Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease Enrolling by invitation

Nitazoxanide in Patients With Ulcerative Colitis Recruiting

A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07333716 on ClinicalTrials.gov ↗ ← All trials in Egypt